Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Acute coronary syndromes

The unfulfilled promise of erythropoietin in patients with MI

Nature Reviews Cardiology volume 8, pages 425–426 (2011)Cite this article

Subjects

Over the past 5–10 years, the positive effects of erythropoietin on myocardial infarction have been reported in several experimental, animal models. However, the results of the REVEAL study call into question the beneficial effects of erythropoietin in humans presenting with myocardial infarction.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Najjar, S. S. et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 305, 1863–1872 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. van Veldhuisen, D. J., Anker, S. D., Ponikowski, P. & Macdougall, I. C. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2011.77.

    Article  CAS  PubMed  Google Scholar 

  3. Lipsic, E. et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J. Am. Coll. Cardiol. 48, 2161–2167 (2006).

    Article  CAS  PubMed  Google Scholar 

  4. Lipsic, E. et al. A single bolus of a long-acting erythropoietin analog darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther. 20, 135–141 (2006).

    Article  CAS  PubMed  Google Scholar 

  5. Voors, A. A. et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur. Heart J. 31, 2593–2600 (2010).

    Article  CAS  PubMed  Google Scholar 

  6. Ott, I. et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ. Cardiovasc. Interv. 3, 408–413 (2010).

    Article  CAS  PubMed  Google Scholar 

  7. Suh, J. W. et al. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int. J. Cardiol. 149, 216–220 (2011).

    Article  PubMed  Google Scholar 

  8. Binbrek, A. S., Rao, N. S., Al, K. N., Assaqqaf, J. & Sobel, B. E. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am. J. Cardiol. 104, 1035–1040 (2009).

    Article  CAS  PubMed  Google Scholar 

  9. Liem, A. et al. Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int. J. Cardiol. 131, 285–287 (2009).

    Article  PubMed  Google Scholar 

  10. Lipsic, E. et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing hematocrit. Eur. J. Heart Fail. 10, 22–29 (2008).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, University Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands

    Peter van der Meer & Dirk J. van Veldhuisen

Authors
  1. Peter van der Meer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dirk J. van Veldhuisen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter van der Meer.

Ethics declarations

Competing interests

D. J. van Veldhuisen declares that he has been a consultant for and received grant/research support from Amgen and Vifor. P. van der Meer declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Meer, P., van Veldhuisen, D. The unfulfilled promise of erythropoietin in patients with MI. Nat Rev Cardiol 8, 425–426 (2011). https://doi.org/10.1038/nrcardio.2011.102

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2011.102

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing